XML 63 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
License Agreements - Syros (Details)
$ / shares in Units, $ in Thousands, shares in Millions
 1 Months Ended 12 Months Ended
Jan. 31, 2018
USD ($)
item
$ / shares
shares
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
License agreements        
Long term investments   $ 221,266 $ 222,301  
Research and development expense   1,458,179 2,215,942 $ 1,154,111
Unrealized gain (loss) on long term investments   (24,072) 10,426 34,458
Syros Pharmaceuticals, Inc.        
License agreements        
Number of program targets | item 7      
Fair value of shares on the issuance date   $ 3,100 10,200  
Ownership percentage (as a percent)   2.00%    
Unrealized gain (loss) on long term investments   $ (7,100) $ 3,700 $ 1,300
Syros Pharmaceuticals, Inc. | Stock purchase agreement        
License agreements        
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.8      
Purchase price of common stock $ 10,000      
Per share price | $ / shares $ 12.61      
Syros Pharmaceuticals, Inc. | Amended stock purchase agreement        
License agreements        
Purchase of common stock under Stock Purchase Agreement (in shares ) | shares 0.1      
Purchase price of common stock $ 1,400      
Per share price | $ / shares $ 9.55      
Syros Pharmaceuticals, Inc. | Maximum        
License agreements        
Target selection and option exercise fee payment $ 54,000      
Syros Pharmaceuticals, Inc. | Development and Regulatory Milestones | Maximum        
License agreements        
Additional milestone payments under the license agreement 50,000      
Syros Pharmaceuticals, Inc. | Commercialization Milestones | Maximum        
License agreements        
Additional milestone payments under the license agreement $ 65,000